Retrospective analysis of suspected adverse drug reactions reported in tertiary care hospital
Abstract
In the past pharmacovigilance happened 174 years back. In 1848, a little girl (Hannah Greener) died due to chloroform anesthetic before the elimination of an infected toenail. The reason for death was investigated, probably girl died of a lethal arrhythmia or pulmonary aspiration. There were 107 deaths occurred in the USA in 1937, for the reason that of the use of sulfanilamide elixir formulation prepared with the solvent used as a diethyl glycol. In 1938, In 1961, happened the thalidomide disaster. Dr. McBride investigated this disaster; he investigated that the 1.5% incidence of congenital malformations in babies had greater than before up to 20% in women who had taken thalidomide medicine for medical treatment during pregnancy. The WHO Programme for International Drug Monitoring (PIDM) was launched by WHO in 1968, after the thalidomide disaster major changed the system of pharmacovigilance globally, necessary to establish national systems for spontaneous ADR monitoring and reporting after consumer use. To conduct a retrospective observational study of adverse drug reactions for inpatient and outpatient in the different clinical departments in a tertiary care hospital. In the present study, a total of 749 adverse drug reaction reporting forms were reported out of which 990 ADRs occurred in 749 patients (inpatients n=502,67.02% and outpatients n=247,32.97%). The overall incidence of ADR was found0.0194%. At least one ADR was recorded in 0.25% of the admitted patients (IPD) and in 0.0067% of the outdoor patients (OPD). In this study male to female ratio was (60.0%) & (40.0%). A total of (82.62%) of ADRs were found nonserious as compared to serious (17.37%). The majority of the ADRs were reported as gastrointestinal system disorders, type-A (60.40%), probable (86.0%), mild (52.72%), preventable (definitely 67.87% and probably 24.24%). Predisposing factors were associated with age (24.14%), polypharmacy (68.38%), and multiple and intercurrent diseases (15.75%). The studies concluded that most adverse drug reactions involved gastrointestinal system disorders and are mild, preventable, and have a probable causality relationship with the suspected drug. ADR monitoring systems monitor unlisted ADRs and other drug-associated problems that have not been recorded during a clinical trial and prior to regulatory authorities to identify signals of new and suspected unexpected unknown ADRs.
Keywords:
World Health Organization, Pharmacovigilance programme of Indian (PvPI), Adverse drug reaction (ADR), Causality AssessmentDOI
https://doi.org/10.25004/IJPSDR.2022.140408References
WHO: International Drug Monitoring, The role of the Hospital, Technical Report Series No. 425, Geneva WHO, 1969.
Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-84.
Lazarou J, Pomeranz BH, Corey PN, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 1200-5.
Schatz N. Stephanie and Weber J. Robert, BCPS; CNS Pharmacy Practice PSAP 2015.
Sriram S, Ghasemi A, Ramasamy R et al. Prevalenace of adverse drug reactions at a private tertiary care hospital in south India. J. Res. Med. Sci. Off. J. IsfahanUniv.Med.Sci.2011;16: 16-25.
WHO: Briefing note, Safety of medicines -adverse drug reactions.
Guidance document for spontaneous Adverse drug reaction reporting, Version 1.0, Chapter 3, Reporting of Adverse drug reactions, Published by ; Indian Pharmacopoeia Commission, National Coordination Centre-Pharmacovigilance programme of India, 2014, Page no. 10-13
United Nations. World population prospects. Annual population 1950-2010 both sexes. Department of Economic and Social Affairs DESA), Population Division, Population Estimates and Projections Section. (http://esa.un.org/wpp/Excel-Data/ population.htm)
Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. 1st ed. Oxford: Oxford University Press 1977 p44.
Medical Dictionary for Regulatory Activities Maintance and Support Services Organization (MedDRA MSSO).(http://www.meddramsso.com)
WHO Collaborating Centre for International Drug Monitoring. WHO Programme for International Drug Monitoring: guide to participating countries - submission in E2B format. Geneva: WHO, 2007.
WHO Collaborating Centre for Drug Statistics Methodology.2007. (http://www.whocc.no/atc_ddd_index)
The use of the WHO-UMC system for standardized case causality assessment. (https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf)
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reaction. Am J Hosp Pharma. 1999;49: 2229-32.
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538
Lau PM, Stewart K, Dooley MJ. Comment: hospital admission resulting from preventable adverse drug reactions. Ann Pharmacother 2003;37:303-12.
Edwards IR. Pharmacological basis of adverse drug reactions. In: speight TM, Holford NHG, editors. Avery’s drug treatment.4th ed. Auckland, New Zealand: Adis International; 1997.p.261-99.
Parthasarathi G, Nyfort-Hansen K, Nahata MC, editors. A text book of clinical pharmacy practice-essential concepts and skills.1st ed. Chennai: Orient Longman Private Limited;2004. p. 86-102.
Veehof LJG, Swewart RE, Haaijer-Ruskamp FM, Meyboom-de Jong B. The development of polypharmacy. A longitudinal study. Family Practice 2000;17(13):261-7
Abdullahi Rabiu Abubakar ,Nordin Bin Simbak , Mainul Haque, Adverse Drug Reactions: Predisposing Factors, Modern Classifications and Causality Assessment , Research J. Pharm. and Tech. 7(9): September 2014, ISSN 0974-3618, Page no. 1091-98.
Singh P, Agrawal M, Hishikar R, Joshi U. Adverse drug reactions at Adverse drug reaction monitoring centre in Raipur: Analysis of spontaneous reports during 1 years, Indian Journal Of Pharmacology 2018; 431-37
Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systemic review and meta-analysis of prospective studies. Br.J Clin Pharmacol 2001:52(1):77-83.
Jha N, Bajracharya O, Namgyal T. Prevalence of adverse drug reactions with commonly prescribe drugs in different hospitals of Kathmandu valley. Kathmandu Univ.Med.J.(KUMJ) 2007; 5:504-510.
Pal SN, Duncombe C, Falzon D, Olsson S. Who strategy for collecting safety data in public health programmes; complementing spontaneous reporting system. Drug saf. 2013; 36:75-81.
Ramakrishnaiah H, Krishnaiah V, Pundarikaksha HP, Ramakrishna V. A prospective study on adverse drug reactions in outpatients and inpatients of medicine department in a tertiary care hospital. In J Basic Clin Pharmacol 2015; 4(3): 515-20.
Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res. 2006 Sep;54(3):226-33.
Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients- a prospective study. Int J Clin Pharmacol Ther 1998;36(10):530-3.
Kanjanarat P, Winterstein AG,Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug event in hospitals : a literature review. Am J Health syst Pharma 2003;60:1750-9
Suh DC, Woodall BS, Shin SK, Hermes-de-Santis ER. Clinical and economic impact of adverse drug reactions in hospitalised patients. Ann Pharmacother 2000; 34:1373-9.
U.S. Food & Drug Administration MCM Emergency Use Authorities. U.S Food & Drug Administration2021
Mathur et al. An evaluation of adverse drug reaction profile at a tertiary care teaching hospital. International Journal of Research and Review. Vol;3 Issue:9; September 2016.
Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S, A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria Journal of Medicine 2017; 53(2): 151-156.
Published
Abstract Display: 478 
PDF Downloads: 388 
